Lightstone Ventures unveils $375M third fund, this time expanding its wishlist in blossoming CNS field
Neuroscience is having a moment right now, and one VC firm straddling the line between biotech and medtech is looking to capitalize on the field’s rapid growth.
Lightstone Ventures has raised $375 million for its third venture fund with an eye on expanding its focus in CNS disease, the firm said Tuesday.
The newest raise brings Lightstone’s total to more than $850 million since the firm was founded back in 2012. So far, that treasure chest has led to investments in around 30 companies split across the biotech and medtech spaces. With its third and largest fund, Lightstone is expecting much the same as before — mostly investments in seed-stage to Series A companies with an eye on “breakthroughs” in patient care, general partner Jason Lettmann told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.